ImmunoPrecise Antibodies (IPA) is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation technology, DeepDisplay™ custom phage libraries, as well as the Abthena™ bispecific program- platforms that blend seamlessly with IPA’s Artemis Intelligence Metadata (AIM)™ capabilities to enable rapid turnaround on additional algorithmic outputs in therapeutic optimization, stability, affinity and manufacturability.
James Kuo, MD, MBA
Chairman and Director
Committee Served: Audit
Dr. James (Jim) Kuo currently serves as Chief Executive Officer of Return Health and Managing Director of Athena Bioventures in La Jolla, CA. He is an experienced biotech industry executive and investor, who brings financial and management experience to the company. During his career, he has held executive positions in private as well as listed bioscience companies in the US, Canada, and Europe. He previously served as CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery Laboratories. Prior to that, Dr. Kuo was Associate Director in Corporate Licensing and Development at Pfizer and Managing Director of HealthCare Ventures, a $378 million venture fund. He received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. Dr. Kuo's undergraduate education is in molecular biology and music history from Haverford College.
Mr. Lundstrom is trained in immunology and international business and has over 30 years’ biopharmaceutical industry experience. He started his career with clinical and business development for Novo Nordisk and subsequently held increasingly executive roles with Sanofi Genzyme and other companies. Beginning in 2012, Mr. Lundstrom helped establish an industry-leading antibody discovery platform business for Ligand Pharmaceuticals and in 2019 formed antibody product company, Abvivo LLC, based on these same transgenic technologies.
Dr. Jennifer Bath
Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.
Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global client relations and high value target teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.
Committees Served: Audit & Compensation
Mr. Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking and institutional fixed income portfolio management before transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. Mr. Smith earned an MBA from Dalhousie University, is a Chartered Financial Analyst and serves in advisory and board positions to multiple private and public ventures.
Committees Served: Compensation & Nomination
Mr. Andreola has over 20 years of business development and financial markets experience including senior management, marketing, and communications roles for early-stage companies. Mr. Andreola is the President, Chief Executive Officer and Director of NameSilo Technologies Corp and a director of Atlas Engineered Products Ltd. Previously in his career, Mr. Andreola was a licensed investment advisor for over 10 years and has facilitated multiple early stage private and public companies in the resource and technology sectors. Mr. Andreola has served on the board of, and in advisory positions to, several public and private companies.
Dr. Robert D. Burke
Committees Served: Audit & Nomination
Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc and a PhD at the University of Alberta.
As part of ImmunoPrecise's shared values of Innovation, Collaboration, and Ownership, we take seriously the responsibility to protect our customer's intellectual property. Data drives every decision in the laboratory, ensuring its accurate and protected at every step is crucial in the success of our customer's projects. ImmunoPrecise has taken a defense-in-depth approach through industry-leading AI-enabled security technologies to protect intellectual property, and data from policy violations, intrusion, and breaches. Security and privacy concerns can be directed to: email@example.com